相关实验视频

Updated: Sep 18, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

使用染色体不稳定性特征预测化学疗法的耐药性

Joe Sneath Thompson^1,2, Laura Madrid², Barbara Hernando¹

¹Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Nature genetics

|June 23, 2025

概括

染色体不稳定标志可以预测化疗耐药性,从而实现个性化癌症治疗. 这种基因组测试可以识别那些不太可能从,高或人环类药物中受益的患者,从而避免有毒副作用.

科学领域:

基因组学就是基因组学.
在瘤学瘤学.
生物标志物发现发现

背景情况:

化疗缺乏精确的生物标志物,导致患者暴露在有毒的副作用中,但没有保证有效性.
当前的治疗模式往往采用一种适合所有人的化学疗法管理方法.

研究的目的:

开发和验证染色体不稳定性 (CIN) 签名生物标志物,用于预测对,税和基化学疗法的耐药性.
评估CIN签名在不同癌症类型和治疗方案中的临床实用性.

主要方法:

使用模拟随机对照生物标志物临床试验对现实世界队列 (n=840) 的回顾性分析.
通过非随机仿真对特定药物-癌症类型组合进行预测能力的验证.
使用全基因组测序,捕获面板测序和无细胞DNA来证明可行性.

主要成果:

在卵巢癌,转移性乳腺癌和转移性前列腺癌中,CIN签名预测了高高的治疗失败风险.
还证明了对卵巢中的白金耐药性和在肉瘤中的反环素耐药性的预测能力.
危险比 (HR) 范围为1.46至7.44,表明CIN特征与治疗耐药性之间存在显著的关联.

结论:

染色体不稳定签名是预测多种癌症类型化学疗法耐药性的有价值的生物标志物.
这些发现支持从一种适合所有人的化疗方法过渡到精确,量身定制的癌症治疗的潜力.
对CIN特征的基因组测试为优化化疗选择和最大限度地降低患者毒性提供了一条途径.

更多相关视频

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Published on: August 19, 2014

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...